Royalty Pharma plc (RPRX)
NASDAQ · Healthcare · Medical - Pharmaceuticals
Profile
Royalty Pharma plc
- Exchange
- NASDAQ
- Ticker
- RPRX
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Country
- US
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Key facts
Royalty Pharma plc: key facts
- Royalty Pharma plc (NASDAQ: RPRX) is a Medical - Pharmaceuticals company in the Healthcare sector.
- In fiscal 2025, Royalty Pharma plc reported revenue of $2.4B and net income of $770.9M.
- Revenue grew 1.0% a year over the last 4 fiscal years.
- Free cash flow was positive in 5 of the last 5 fiscal years.
- Net income was positive in 5 of the last 5 fiscal years.
- Over the last twelve months, revenue was $2.5B and net income was $815.3M.
MonkScore
Royalty Pharma plc's MonkScore
MonkScore
MonkScore range: 40–50
as of October 2026
Sector rank: 378 of 628 in Healthcare
How this score is madeDisclaimer
Pillar ranges
- Growth10–20
- Profitability80–90
- Quality40–50
- Market Conviction60–70
- Safety60–70
The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–10 to 90–100.
Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.
Fundamentals
Figures from the statements
Royalty Pharma plc's annual figures and the last twelve months, in USD. Last report: 30 June 2026.
| Figure | Last 12 months | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $2.5B | $2.4B | $2.3B | $2.4B | $2.2B | $2.3B |
| Gross profit | $2.3B | $2.4B | $2.3B | $2.4B | $2.2B | $2.3B |
| Operating income | $1.6B | $1.6B | $1.3B | $1.5B | $307.1M | $1.4B |
| Net income | $815.3M | $770.9M | $859.0M | $1.1B | $42.8M | $619.7M |
| Operating cash flow | $3.0B | $2.5B | $2.8B | $3.0B | $2.1B | $2.0B |
| Capital expenditure | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
| Free cash flow | $3.0B | $2.5B | $2.8B | $3.0B | $2.1B | $2.0B |
| Total debt | $9.0B | $9.0B | $7.6B | $6.1B | $7.1B | $7.1B |
| Cash | $812.0M | $618.7M | $929.0M | $477.0M | $1.7B | $1.5B |
Revenue growth a year
- 1-year
- 5.1%
- 3-year
- 2.1%
- 4-year
- 1.0%
Compound growth between fiscal years.
Peers
Similar companies
- Corcept Therapeutics IncorporatedNASDAQ:CORTMonkScore range: 90–100
- Kiniksa Pharmaceuticals International, plcNASDAQ:KNSAMonkScore range: 90–100
- Liquidia CorporationNASDAQ:LQDAMonkScore range: 90–100
Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click
MonkStreet provides research, not investment advice.
Page built on 31 October 2026.